I agree that this site is using cookies. You can find further informations here.
X
Macro, M.
~ 100  results:
Search for persons X
?
1

B01 VENETOCLAX TARGETED THERAPY in AL AMYLOIDOSIS PATIENTS:..:

Roussel, M. ; Pirotte, M. ; Gounot, R....
HemaSphere.  7 (2023)  S2 - p. 4-4 , 2023
Link: https://doi.org/10.1097/..
 
?
2

Long‐term analysis of the RiBVD phase II trial reveals the ..:

Carras, S. ; Torroja, A. ; Emadali, A....
Hematological Oncology.  41 (2023)  S2 - p. 481-483 , 2023
Link: https://doi.org/10.1002/..
 
?
3

Real-world effectiveness of ixazomib combined with lenalido..:

Macro, M. ; Hulin, C. ; Vincent, L....
Annals of Hematology.  102 (2023)  8 - p. 2137-2151 , 2023
Link: https://doi.org/10.1007/..
 
?
4

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) ..:

Weisel, K. ; Kumar, S. ; Moreau, P....
HemaSphere.  7 (2023)  S2 - p. 14-15 , 2023
Link: https://doi.org/10.1097/..
 
?
5

S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASON..:

Touzeau, C. ; Perrrot, A. ; Hulin, C....
HemaSphere.  6 (2022)  - p. 77-78 , 2022
Link: https://doi.org/10.1097/..
 
?
6

P925: IMPACT OF PRIOR TREATMENT EXPOSURE ON THE EFFECTIVENE..:

Lee, H. C. ; Ramasamy, K. ; Macro, M....
HemaSphere.  6 (2022)  - p. 815-816 , 2022
Link: https://doi.org/10.1097/..
 
?
7

P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RE..:

Bobin, A. ; Manier, S. ; De Keizer, J....
HemaSphere.  6 (2022)  - p. 783-784 , 2022
Link: https://doi.org/10.1097/..
 
?
8

P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-R..:

Facon, T. ; Kumar, S. K. ; Plesner, T....
HemaSphere.  6 (2022)  - p. 826-827 , 2022
Link: https://doi.org/10.1097/..
 
?
9

P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DAR..:

Macro, M. ; Touzeau, C. ; Mariette, C....
HemaSphere.  6 (2022)  - p. 819-820 , 2022
Link: https://doi.org/10.1097/..
 
?
10

P955: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA P..:

Hulin, C. ; Macro, M. ; Perrot, A....
HemaSphere.  6 (2022)  - p. 845-846 , 2022
Link: https://doi.org/10.1097/..
 
?
11

P956: EMMY COHORT: MANAGEMENT OF NEWLY DIAGNOSED OR RELAPSE..:

Macro, M. ; Decaux, O. ; Perrot, A....
HemaSphere.  6 (2022)  - p. 846-847 , 2022
Link: https://doi.org/10.1097/..
 
?
12

P904: CILTACABTAGENE AUTOLEUCEL VS TREATMENTS FROM REAL-WOR..:

Decaux, O. ; Hulin, C. ; Perrot, A....
HemaSphere.  6 (2022)  - p. 795-796 , 2022
Link: https://doi.org/10.1097/..
 
?
13

P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A L..:

Schavgoulidze, A. ; Perrot, A. ; Cazaubiel, T....
HemaSphere.  6 (2022)  - p. 765-766 , 2022
Link: https://doi.org/10.1097/..
 
?
14

HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DIS..:

Cottereau, A. ; Vercellino, L. ; Casasnovas, O....
Hematological Oncology.  37 (2019)  S2 - p. 49-50 , 2019
Link: https://doi.org/10.1002/..
 
?
15

FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLIN..:

Gressin, R. ; Daguindau, N. ; Tempescul, A....
Hematological Oncology.  35 (2017)  S2 - p. 141-142 , 2017
Link: https://doi.org/10.1002/..
 
1-15